A Study of MEDI1191 in sequential and concurrent combination with Durvalumab in Subjects with Advanced Solid Tumors

Trial Identifier: D8510C00001
Sponsor:MedImmune, LLC
Start Date:May 2019
Primary Completion Date: August 2023
Study Completion Date: August 2023
Condition: Cancer - Other

Available Languages

For questions about your Trial Results Summary, please see Sponsor contact section within your Trial Results Summary.

No documents have been posted yet.

Trial Locations

US, RI Providence, RI, US, 02903
US, CA La Jolla, CA, US, 92093
US, CA Los Angeles, CA, US, 90025
US, CA Los Angeles, CA, US, 90089
US, CA Newport Beach, CA, US, 92663
US, TX Houston, TX, US, 77030
US, NY Bronx, NY, US, 10461
US, NY New York, NY, US, 10065
US, NY New York, NY, US, 10029
ES Barcelona, ES, 08035
ES Madrid, ES, 28027
ES Pamplona, ES, 31008
FR Villejuif, FR, 94800
NL Groningen, NL, 9713 GZ